Inhibition of histone deacetylase 4 increases cytotoxicity of docetaxel in gastric cancer cells

Proteomics - Clinical Applications

Volumn 8, Issue 11-12, 2014, Pages 924-931

  Colarossi, Lorenzo ^a,b   Memeo, Lorenzo ^c,d   Colarossi, Cristina ^c   Aiello, Eleonora ^c   Iuppa, Antonio ^c   Espina, Virginia ^a   Liotta, Lance ^a   Mueller, Claudius ^a  

^a GEORGE MASON UNIVERSITY   (United States)

^b Fondazione IOM   (Italy)

^c Mediterranean Institute of Oncology   (Italy)

^d IOM Ricerca srl   (Italy)

Author keywords

Docetaxel; Gastric cancer; Histone deacetylation; Laser capture microdissection; Reverse phase protein microarrays

Indexed keywords

3 [4 [3 (3 FLUOROPHENYL) 3 OXO 1 PROPENYL] 1 METHYL 1H PYRROL 2 YL]ACRYLOHYDROXAMIC ACID; CASPASE 3; CASPASE 9; CISPLATIN; DOCETAXEL; HISTONE DEACETYLASE 4; HISTONE H3; LYSINE; ANTINEOPLASTIC AGENTS; BIOLOGICAL MARKERS; HDAC4 PROTEIN, HUMAN; HISTONE DEACETYLASE INHIBITORS; HISTONE DEACETYLASES; HISTONES; HYDROXAMIC ACIDS; MC1568; PYRROLES; REPRESSOR PROTEINS; TAXOIDS;

ADULT; AGED; APOPTOSIS; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER INHIBITION; CLINICAL ARTICLE; CONTROLLED STUDY; CYTOSTASIS; DRUG CYTOTOXICITY; DRUG POTENTIATION; ENZYME INHIBITION; FEMALE; GASTRIC CANCER CELL LINE; HISTONE ACETYLATION; HUMAN; HUMAN CELL; HUMAN TISSUE; LASER MICRODISSECTION; MALE; MIDDLE AGED; PRIORITY JOURNAL; PROTEIN CLEAVAGE; PROTEIN EXPRESSION; STOMACH CANCER; VERY ELDERLY; ACETYLATION; AGED, 80 AND OVER; ANTAGONISTS AND INHIBITORS; CELL LINE, TUMOR; CELL SURVIVAL; DRUG EFFECTS; DRUG SYNERGISM; ENZYMOLOGY; HUMANS; IMMUNOHISTOCHEMISTRY; METABOLISM; PATHOLOGY; STOMACH NEOPLASMS;

ACETYLATION; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS; APOPTOSIS; BIOLOGICAL MARKERS; CELL LINE, TUMOR; CELL SURVIVAL; CISPLATIN; DRUG SYNERGISM; FEMALE; HISTONE DEACETYLASE INHIBITORS; HISTONE DEACETYLASES; HISTONES; HUMANS; HYDROXAMIC ACIDS; IMMUNOHISTOCHEMISTRY; MALE; MIDDLE AGED; PYRROLES; REPRESSOR PROTEINS; STOMACH NEOPLASMS; TAXOIDS;

EID: 84912570684     PISSN: 18628346     EISSN: 18628354     Source Type: Journal    
DOI: 10.1002/prca.201400058     Document Type: Article

References (38)

1. Figueiredo, C., Garcia-Gonzalez, M. A., Machado, J. C., Molecular pathogenesis of gastric cancer. Helicobacter 2013, 18, 28-33.
2. Yakirevich, E., Resnick, M. B., Pathology of gastric cancer and its precursor lesions. Gastroenterol. Clin. North Am. 2013, 42, 261-284.
3. De Ruijter, A. J. M., van Gennip, A. H., Caron, H. N., Kemp, S. et al., Histone deacetylases (HDACs): characterization of the classical HDAC family. Biochem. J. 2003, 370, 737-749.
4. Mai, A., Massa, S., Pezzi, R., Simeoni, S. et al., Class II (IIa)-selective histone deacetylase inhibitors. 1. Synthesis and biological evaluation of novel (aryloxopropenyl)pyrrolyl hydroxyamides. J. Med. Chem. 2005, 48, 3344-3353.
5. Glozak, M. A., Seto, E., Histone deacetylases and cancer. Oncogene 2007, 26, 5420-5432.
6. Haberland, M., Montgomery, R. L., Olson, E. N., The many roles of histone deacetylases in development and physiology: implications for disease and therapy. Nat. Rev. Genet. 2009, 10, 32-42.
7. Clocchiatti, A., Di Giorgio, E., Demarchi, F., Brancolini, C., Beside the MEF2 axis: unconventional functions of HDAC4. Cell. Signal. 2013, 25, 269-276.
8. Geng, H., Harvey, C. T., Pittsenbarger, J., Liu, Q. et al., HDAC4 protein regulates HIF1α protein lysine acetylation and cancer cell response to hypoxia. J. Biol. Chem. 2011, 286, 38095-38102.
9. Nebbioso, A., Manzo, F., Miceli, M., Conte, M. et al., Selective class II HDAC inhibitors impair myogenesis by modulating the stability and activity of HDAC-MEF2 complexes. EMBO Rep. 2009, 10, 776-782.
10. Sando, R., Gounko, N., Pieraut, S., Liao, L. et al., Hdac4 governs a transcriptional program essential for synaptic plasticity and memory. Cell 2012, 151, 821-834.
11. Spallotta, F., Tardivo, S., Nanni, S., Rosati, J. D. et al., Detrimental effect of class-selective histone deacetylase inhibitors during tissue regeneration following hindlimb ischemia. J. Biol. Chem. 2013, 288, 22915-22929.
12. Ropero, S., Esteller, M., The role of histone deacetylases (HDACs) in human cancer. Mol. Oncol. 2007, 1, 19-25.
13. Weichert, W., Röske, A., Gekeler, V., Beckers, T. et al., Association of patterns of class I histone deacetylase expression with patient prognosis in gastric cancer: a retrospective analysis. Lancet. Oncol. 2008, 9, 139-148.
14. Sudo, T., Mimori, K., Nishida, N., Kogo, R. et al., Histone deacetylase 1 expression in gastric cancer. Oncol. Rep. 2011, 26, 777-782.
15. Mutze, K., Langer, R., Becker, K., Ott, K. et al., Histone deacetylase (HDAC) 1 and 2 expression and chemotherapy in gastric cancer. Ann. Surg. Oncol. 2010, 17, 3336-3343.
16. Gallagher, R. I., Blakely, S. R., Liotta, L. A., Espina, V., Laser capture microdissection: Arcturus(XT) infrared capture and UV cutting methods. Methods Mol. Biol. 2012, 823, 157-178.
17. Liotta, L. A., Espina, V., Mehta, A. I., Calvert, V. et al., Protein microarrays: meeting analytical challenges for clinical applications. Cancer Cell 2003, 3, 317-325.
18. VanMeter, A. J., Rodriguez, A. S., Bowman, E. D., Jen, J. et al., Laser capture microdissection and protein microarray analysis of human non-small cell lung cancer: differential epidermal growth factor receptor (EGPR) phosphorylation events associated with mutated EGFR compared with wild type. Mol. Cell. Proteomics 2008, 7, 1902-1924.
19. Mueller, C., Liotta, L. A., Espina, V., Reverse phase protein microarrays advance to use in clinical trials. Mol. Oncol. 2010, 4, 461-481.
20. Biasutto, L., Chiechi, A., Couch, R., Liotta, L. A. et al., Retinal pigment epithelium (RPE) exosomes contain signaling phosphoproteins affected by oxidative stress. Exp. Cell Res. 2013, 319, 2113-2123.
21. Chiechi, A., Mueller, C., Boehm, K. M., Romano, A. et al., Improved data normalization methods for reverse phase protein microarray analysis of complex biological samples. BioTechniques 2012, 0, 1-7.
22. R Core Team, R: A Language and Environment for Statistical Computing, R Foundation for Statistical Computing, Vienna, Austria 2012.
23. Huber, K., Doyon, G., Plaks, J., Fyne, E. et al., Inhibitors of histone deacetylases: correlation between isoform specificity and reactivation of HIV type 1 (HIV-1) from latently infected cells. J. Biol. Chem. 2011, 286, 22211-22218.
24. Ilson, D. H., Docetaxel, cisplatin, and fluorouracil in gastric cancer: does the punishment fit the crime? J. Clin. Oncol. 2007, 25, 3188-3190.
25. Paroni, G., Cernotta, N., Dello Russo, C., Gallinari, P. et al., PP2A regulates HDAC4 nuclear import. Mol. Biol. Cell 2008, 19, 655-667.
26. Guise, A. J., Greco, T. M., Zhang, I. Y., Yu, F. et al., Aurora B-dependent regulation of class iia histone deacetylases by mitotic nuclear localization signal phosphorylation. Mol. Cell. Proteomics 2012, 11, 1220-1229.
27. Park, J. G., Gazdar, A. F., Biology of colorectal and gastric cancer cell lines. J. Cell Biochem. Suppl. 1996, 24, 131-141.
28. Calcagno, D.-Q., Leal, M.-F., Assumpcao, P.-P., Smith, M.-A.-C. et al., MYC and gastric adenocarcinoma carcinogenesis. World J. Gastroenterol. 2008, 14, 5962-5968.
29. Labisso, W. L., Wirth, M., Stojanovic, N., Stauber, R. H. et al., MYC directs transcription of MCL1 and eIF4E genes to control sensitivity of gastric cancer cells toward HDAC inhibitors. Cell Cycle 2012, 11, 1593-1602.
30. Stronach, E. A., Alfraidi, A., Rama, N., Datler, C. et al., HDAC4-regulated Stat1 activation mediates platinum resistance in ovarian cancer. Cancer Res. 2011, 71, 4412-4422.
31. Nishiyama, M., Wada, S., Docetaxel: its role in current and future treatments for advanced gastric cancer. Gastric Cancer 2009, 12, 132-141.
32. Baker, S. D., Zhao, M., Lee, C. K. K., Verweij, J. et al., Comparative pharmacokinetics of weekly and every-three-weeks docetaxel. Clin. Cancer Res. 2004, 10, 1976-1983.
33. Kramer, O. H., Knauer, S. K., Greiner, G., Jandt, E. et al., A phosphorylation-acetylation switch regulates STAT1 signaling. Genes Dev. 2009, 23, 223-235.
34. Aron, J. L., Parthun, M. R., Marcucci, G., Kitada, S. et al., Depsipeptide (FR901228) induces histone acetylation and inhibition of histone deacetylase in chronic lymphocytic leukemia cells concurrent with activation of Caspase 8-mediated apoptosis and down-regulation of c-FLIP protein. Blood 2003, 102, 652-658.
35. Bártová, E., Pacherník, J., Harničarová, A., Kovařík, A. et al., Nuclear levels and patterns of histone H3 modification and HP1 proteins after inhibition of histone deacetylases. J. Cell Sci. 2005, 118, 5035-5046.
36. Tang, Y.-A., Wen, W.-L., Chang, J.-W., Wei, T.-T. et al., A novel histone deacetylase inhibitor exhibits antitumor activity via apoptosis induction, F-actin disruption and gene acetylation in Lung cancer. PLoS One 2010, 5, e12417.
37. Bolden, J. E., Peart, M. J., Johnstone, R. W., Anticancer activities of histone deacetylase inhibitors. Nat. Rev. Drug Discov. 2006, 5, 769-784.
38. Ma, X., Ezzeldin, H. H., Diasio, R. B., Histone deacetylase inhibitors: current status and overview of recent clinical trials. Drugs 2009, 69, 1911-1934.